CIK 0000875045 · Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330112644
- Phone
- 6176792000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-03 | Mantas Jesus B Director | Grant or award | +890 | 2,045 | ||
| 2020-06-03 | LEAMING NANCY Director | Grant or award | +890 | 12,988 | ||
| 2020-06-03 | HAWKINS WILLIAM A Director | Grant or award | +890 | 2,045 | ||
| 2020-06-03 | DORSA CAROLINE Director | Grant or award | +890 | 21,097 | ||
| 2020-06-03 | DENNER ALEXANDER J Director | Grant or award | +890 | 12,954 | ||
| 2020-03-11 | SHERWIN STEPHEN A Director | Option exercise | +10,923 | $58.46 | $639K | 16,517 |
| 2020-03-11 | SHERWIN STEPHEN A Director | Sale | −2,164 | $295.22 | $639K | 14,353 |
| 2020-03-11 | SHERWIN STEPHEN A Director | Option exercise | +1,355 | $58.46 | $79K | 15,708 |
| 2020-03-11 | SHERWIN STEPHEN A Director | Sale | −270 | $295.29 | $80K | 15,438 |
| 2020-03-11 | SHERWIN STEPHEN A Director | Option exercise · Stock Option (Right to Buy) | −10,923 | 0 | ||
| 2020-03-11 | SHERWIN STEPHEN A Director | Option exercise · Stock Option (Right to Buy) | −1,355 | 0 | ||
| 2020-02-15 | Vounatsos Michel Chief Executive Officer | Option exercise | +4,847 | 33,775.32 | ||
| 2020-02-15 | Vounatsos Michel Chief Executive Officer | Shares withheld for taxes | −2,150 | $333.00 | $716K | 31,625.32 |
| 2020-02-15 | Vounatsos Michel Chief Executive Officer | Option exercise · Restricted Stock Unit | −4,847 | 3,657 | ||
| 2020-02-15 | Vounatsos Michel Chief Executive Officer | Other disposition · Restricted Stock Unit | −3,657 | 0 | ||
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Option exercise | +1,213 | 15,019.25 | ||
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Shares withheld for taxes | −538 | $333.00 | $179K | 14,481.25 |
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Option exercise · Restricted Stock Unit | −1,213 | 915 | ||
| 2020-02-15 | Sandrock Alfred EVP, Research & Development | Other disposition · Restricted Stock Unit | −915 | 0 | ||
| 2020-02-15 | Galdes Alphonse EVP Pharmaceutical Oper & Tech | Option exercise | +441 | 2,672.26 |
Page 42 of 45 · 886 trades